PT  - JOURNAL ARTICLE
AU  - Maria Gonzalez-Cao
AU  - Mónica Antoñanzas Basa
AU  - Teresa Puertolas
AU  - Eva Muñoz
AU  - José Luis Manzano
AU  - Cristina Carrera
AU  - Ivan Marquez-Rodas
AU  - Pilar Lopez Criado
AU  - Juan Francisco Rodriguez Moreno
AU  - Almudena García Castaño
AU  - Juan Martín-Liberal
AU  - Pedro Rodríguez-Jiménez
AU  - Susana Puig
AU  - Pablo Cerezuela
AU  - Marta Feito Rodríguez
AU  - Belén Rubio Viqueira
AU  - Guillermo Crespo
AU  - Pablo Luna Fra
AU  - Cristina Aguayo Zamora
AU  - Pablo Ayala de Miguel
AU  - Rosa Feltes Ochoa
AU  - Lara Valles
AU  - Ana Drozdowskyj
AU  - Ainara Soria
AU  - Cayetana Maldonado Seral
AU  - Luis Fernández-Morales
AU  - Rafael Rosell
AU  - Mariano Provencio
AU  - Alfonso Berrocal
AU  - for the Spanish Melanoma Group (GEM).
TI  - Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
AID  - 10.1101/2020.05.19.20106971
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20106971
4099  - http://medrxiv.org/content/early/2020/05/21/2020.05.19.20106971.short
4100  - http://medrxiv.org/content/early/2020/05/21/2020.05.19.20106971.full
AB  - Background Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating effects on the health care system, affecting also cancer patient care. Data about COVID-19 infection in cancer patients are scarce, and they point out a higher risk of complications due to the viral infection in this population. Moreover, cancer treatments could increase viral complications, specially those treatments based on the use of immunotherapy with checkpoints antibodies. There are no clinical data about the safety of immune check point antibodies in cancer patients when they become infected by SARS-CoV-2. As checkpoint inhibitors, mainly anti PD-1 and anti CTLA-4 antibodies, are an effective treatment for most melanoma patients, avoiding their use during the pandemic could lead to a decrease in the chances of curing melanoma.Methods In Spain we have started a national registry of melanoma patients infected by SARS-Cov-2 since April 1st, 2020. A retrospective analysis of patients included in the Spanish registery has been performed weekly since the activation of the study. Interim analysis shows unexpected findings about cancer treatment safety in SARS-Cov-2 infected melanoma patients, so a rapid communication to the scientific community is mandatoryResults Fifty patients have been included as of May 17th, 2020. Median age is 69 years (range 6 to 94 years), 27 (54%) patients are males and 36 (70%) patients have stage IV melanoma. Twenty-two (44%) patients were on active anticancer treatment with anti PD-1 antibodies, 16 (32%) patients were on treatment with BRAF plus MEK inhibitors and 12 (24%) patients were not on active cancer treatment. COVID-19 episode has been resolved in 43 cases, including 30 (70%) patients cured, four (9%) patients that have died due to melanoma progression, and nine (21%) patients that have died from COVID-19. Mortality rates from COVID-19 according to melanoma treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer treatment, respectively.Conclusion These preliminary findings show that the risk of death in those patients under going treatment with anti PD-1 antibodies does not exceed the global risk of death in this population. These results could be relevant in order to select melanoma therapy during the COVID-19 pandemicCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatabase and analysis is available for the Spanish Melanoma Group